◎ Sugi Atlas

Atlas / Drug / Abiraterone

Abiraterone

drug
On this page

Also known as AbirateronaCB 7598CB-7598NSC-741232ZytigaABIRATERONE (CB-7598)

Summary

Abiraterone (CHEMBL254328) is an approved small-molecule antineoplastic agent (ATC L02BX03) targeting CYP17A1; indicated across 7 conditions including neoplasm and prostate carcinoma; with CIViC clinical evidence for 7 variant-indication associations (e.g. BRCA1 Mutation OR BRCA2 Mutation in castration-resistant prostate carcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L02BX03
  • Targets: 1 (CYP17A1)
  • Indications: 7 conditions
  • Clinical trials: 135
  • Precision-oncology evidence (CIViC): 7 variant–indication associations
  • Chemistry: 349.5 Da · C24H31NO

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL254328
NameAbiraterone
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID132971
ChEBICHEBI:68642
ATCL02BX03
Molecular formulaC24H31NO
Molecular weight349.5
InChIKeyGZOSMCIZMLWJML-VJLLXTKPSA-N

SMILES: C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O

IUPAC name: (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol

ChEBI definition: A 3β-sterol that is androsta-5,16-dien-3β-ol substituted at position 17 by a 3-pyridyl group. Administered as the O-acetate, it is used for treatment of metastatic castrate-resistant prostate cancer.

Pharmacological roles (ChEBI): antineoplastic agent, EC 1.14.99.9 (steroid 17α-monooxygenase) inhibitor.

Also known as: Abiraterona, Abiraterone, CB 7598, CB-7598, NSC-741232, Zytiga, abiraterone, ABIRATERONE, ABIRATERONE (CB-7598), Abiraterone (CB-7598)

Patent coverage: 5,749 distinct patent families (22,316 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 22,134 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
CYP17A1CYP17A1Inhibition7.30.1%P05093

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Cytochrome P450 11B1, mitochondrial, Cytochrome P450 11B2, mitochondrial, Steroid 21-hydroxylase, Cytochrome P450 3A4, Steroid 17-alpha-hydroxylase/17,20 lyase, Steroid 17-alpha-hydroxylase/17,20 lyase.

Bioactivity

ChEMBL activities: 46 potent at pChembl ≥ 5 of 46 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
CYP17A18.7IC502nMCHEMBL_ACT_24747411
CYP17A18.7IC502nMCHEMBL_ACT_25514413
CYP17A18.54IC502.9nMCHEMBL_ACT_982893
CYP17A18.4IC504nMCHEMBL_ACT_87981
CYP17A18.4IC504nMCHEMBL_ACT_982894
CYP17A18.31IC504.94nMCHEMBL_ACT_18505295
CYP17A18.3IC505nMCHEMBL_ACT_14538101
CYP17A18.03IC509.4nMCHEMBL_ACT_18505308
P117157.9IC5012.5nMCHEMBL_ACT_13836663
P117157.9IC5012.5nMCHEMBL_ACT_16738913
P117157.61IC5024.7nMCHEMBL_ACT_18115396
CYP17A17.54IC5029nMCHEMBL_ACT_17803331
CYP21A27.49IC5032.4nMCHEMBL_ACT_18505284
CYP17A17.45IC5035.8nMCHEMBL_ACT_18115375
CYP17A17.32IC5048nMCHEMBL_ACT_19474737
CYP17A17.14IC5072nMCHEMBL_ACT_12085782
CYP17A17.14IC5072nMCHEMBL_ACT_12678151
CYP17A17.14IC5072nMCHEMBL_ACT_13430199
CYP17A17.14IC5072nMCHEMBL_ACT_2072528
CYP17A17.14IC5072nMCHEMBL_ACT_2093266
CYP17A17.14IC5072nMCHEMBL_ACT_2226857
CYP17A17.14IC5072nMCHEMBL_ACT_2227638
CYP17A17.14IC5072nMCHEMBL_ACT_2680497
CYP17A17.14IC5072nMCHEMBL_ACT_3364930
CYP17A17.14IC5072nMCHEMBL_ACT_3408084
CYP17A16.89IC50130nMCHEMBL_ACT_18710924
CYP17A16.89IC50130nMCHEMBL_ACT_27120014
P117156.66IC50220nMCHEMBL_ACT_2093273
CYP3A46.64IC50230nMCHEMBL_ACT_18505303
CYP21A26.53IC50296nMCHEMBL_ACT_18710938

Target pathways

Aggregated over 1 target gene(s): CYP17A1.

Top Reactome pathways

3 total, by targets touching each:

PathwayTargetsGenes
Androgen biosynthesis1CYP17A1
Glucocorticoid biosynthesis1CYP17A1
Defective CYP17A1 causes AH51CYP17A1

Dominant GO biological processes

GO termTargets
steroid biosynthetic process1
androgen biosynthetic process1
glucocorticoid biosynthetic process1
sex differentiation1
steroid metabolic process1
cortisol biosynthetic process1
hormone biosynthetic process1
progesterone metabolic process1
lipid metabolic process1
hormone metabolic process1
olefinic compound metabolic process1

Indications & clinical

Indications

7 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
prostate carcinoma3MONDO:0005159EFO:0001663
prostate adenocarcinoma3MONDO:0005082EFO:0000673
metastatic prostate carcinoma3MONDO:0004956EFO:0000196
prostate cancer3MONDO:0008315MONDO:0021259

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 135.

Phase distribution

PhaseTrials
PHASE254
PHASE127
PHASE320
PHASE1/PHASE217
Not specified11
PHASE2/PHASE33
PHASE42
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07001709PHASE4RECRUITINGDetermining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)
NCT01995513PHASE4COMPLETEDSafety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
NCT00268476PHASE2/PHASE3ACTIVE_NOT_RECRUITINGSystemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
NCT03678025PHASE3RECRUITINGStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03748641PHASE3ACTIVE_NOT_RECRUITINGA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03903835PHASE3RECRUITINGProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
NCT04497844PHASE3ACTIVE_NOT_RECRUITINGA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
NCT04647526PHASE3ACTIVE_NOT_RECRUITINGStudy Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
NCT04787744PHASE2/PHASE3RECRUITINGVeterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT05288166PHASE3ACTIVE_NOT_RECRUITINGA Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT06520345PHASE3RECRUITINGThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
NCT06592924PHASE3RECRUITINGDocetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06691984PHASE3ACTIVE_NOT_RECRUITINGPhase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06764485PHASE3RECRUITINGA Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT07611110PHASE3RECRUITINGAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT01591122PHASE3COMPLETEDStudy of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
NCT01715285PHASE3COMPLETEDA Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
NCT01949337PHASE3UNKNOWNEnzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
NCT02043678PHASE3COMPLETEDRadium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
NCT02975934PHASE3COMPLETEDA Study of Rucaparib Versus Physician’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT03072238PHASE3COMPLETEDIpatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT03295565PHASE2/PHASE3COMPLETEDOptimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel
NCT04139772PHASE3UNKNOWNDocetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.
NCT04844749PHASE3TERMINATEDEfficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
NCT04887506PHASE3COMPLETEDTAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
NCT02861573PHASE1/PHASE2RECRUITINGStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
NCT03141671PHASE2ACTIVE_NOT_RECRUITINGRandomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
NCT03431350PHASE2ACTIVE_NOT_RECRUITINGA Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT04175431PHASE2RECRUITINGProstate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
NCT04262154PHASE2ACTIVE_NOT_RECRUITINGStudy of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
NCT04748042PHASE2ACTIVE_NOT_RECRUITINGFocal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
NCT04812366PHASE2RECRUITINGGenomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
NCT05751941PHASE2RECRUITINGStudy of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
NCT05914116PHASE1/PHASE2RECRUITINGA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT06173362PHASE2RECRUITINGAbiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
NCT06378866PHASE2RECRUITINGStereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
NCT06457919PHASE1/PHASE2RECRUITINGA Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
NCT06500247PHASE2NOT_YET_RECRUITINGDarxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.
NCT06568094PHASE1/PHASE2RECRUITINGA Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
NCT06689163PHASE1/PHASE2RECRUITINGA Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

Clinical evidence (CIViC)

Variant × indication × effect (7 predictive associations from 13 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
BRCA1 Mutation OR BRCA2 MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseAbiraterone + NiraparibCIViC AEID11738
TSPYL1 P62SProstate CancerSensitivity/ResponsePrednisone + AbirateroneCIViC BEID5861
AR AR-V7Prostate CancerResistanceAbiraterone + EnzalutamideCIViC BEID12463 +5
AR AR-V7Prostate CancerResistanceEnzalutamide + AbirateroneCIViC BEID12464 +1
AR AR alternative transcriptsProstate CancerResistanceAbiraterone + EnzalutamideCIViC BEID9578
AR Overexpression of AR-V9Prostate CancerResistanceAbirateroneCIViC BEID9491
TSPYL1 P62SProstate CancerSensitivity/ResponseAbirateroneCIViC DEID8947

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 14 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

20 molecules share ≥1 primary target. Top 20 by shared-target count:

MoleculeSourceStatusShared targets
CLOTRIMAZOLEChEMBL + PubChemPhase 4 (approved)CYP17A1
ECONAZOLEChEMBL + PubChemPhase 4 (approved)CYP17A1
MICONAZOLEChEMBL + PubChemPhase 4 (approved)CYP17A1
OSILODROSTATChEMBL + PubChemPhase 4 (approved)CYP17A1
AMINOGLUTETHIMIDEChEMBLPhase 4 (approved)CYP17A1
BIFONAZOLEChEMBLPhase 4 (approved)CYP17A1
ISOCONAZOLEChEMBLPhase 4 (approved)CYP17A1
KETOCONAZOLEChEMBLPhase 4 (approved)CYP17A1
POSACONAZOLEChEMBLPhase 4 (approved)CYP17A1
TESTOSTERONE PROPIONATEChEMBLPhase 4 (approved)CYP17A1
TIOCONAZOLEChEMBLPhase 4 (approved)CYP17A1
GALETERONEChEMBLPhase 3CYP17A1
ORTERONELChEMBLPhase 3CYP17A1
AZALANSTATChEMBLPhase 2CYP17A1
BicalutamidePubChemApprovedCYP17A1
EnzalutamidePubChemApprovedCYP17A1
FluconazolePubChemApprovedCYP17A1
FlutamidePubChemApprovedCYP17A1
LetrozolePubChemApprovedCYP17A1
MetyraponePubChemApprovedCYP17A1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot